Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Fulcrum Therapeutics stock | $23.47

Learn how to easily invest in Fulcrum Therapeutics stock.

Fulcrum Therapeutics Inc is a biotechnology business based in the US. Fulcrum Therapeutics shares (FULC) are listed on the NASDAQ and all prices are listed in US Dollars. Fulcrum Therapeutics employs 73 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Fulcrum Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FULC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Fulcrum Therapeutics stock price (NASDAQ: FULC)

Use our graph to track the performance of FULC stocks over time.

Fulcrum Therapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$23.47
52-week range$6.85 - $33.10
50-day moving average $27.57
200-day moving average $15.48
Wall St. target price$35.43
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.47

Buy Fulcrum Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Fulcrum Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Fulcrum Therapeutics price performance over time

Historical closes compared with the close of $23.47 from 2021-10-20

1 week (2021-10-14) -13.81%
1 month (2021-09-21) -23.97%
3 months (2021-07-21) 158.48%
6 months (2021-04-21) 103.73%
1 year (2020-10-21) 129.65%
2 years (2019-10-21) 426.23%
3 years (2018-10-17) N/A
5 years (2016-10-17) N/A

Fulcrum Therapeutics financials

Revenue TTM $15.2 million
Gross profit TTM $-46,839,000
Return on assets TTM -32.55%
Return on equity TTM -62.94%
Profit margin 0%
Book value $3.40
Market capitalisation $1 billion

TTM: trailing 12 months

Shorting Fulcrum Therapeutics shares

There are currently 2.1 million Fulcrum Therapeutics shares held short by investors – that's known as Fulcrum Therapeutics's "short interest". This figure is 21.2% up from 1.7 million last month.

There are a few different ways that this level of interest in shorting Fulcrum Therapeutics shares can be evaluated.

Fulcrum Therapeutics's "short interest ratio" (SIR)

Fulcrum Therapeutics's "short interest ratio" (SIR) is the quantity of Fulcrum Therapeutics shares currently shorted divided by the average quantity of Fulcrum Therapeutics shares traded daily (recently around 666056.4516129). Fulcrum Therapeutics's SIR currently stands at 3.1. In other words for every 100,000 Fulcrum Therapeutics shares traded daily on the market, roughly 3100 shares are currently held short.

However Fulcrum Therapeutics's short interest can also be evaluated against the total number of Fulcrum Therapeutics shares, or, against the total number of tradable Fulcrum Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fulcrum Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Fulcrum Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0954% of the tradable shares (for every 100,000 tradable Fulcrum Therapeutics shares, roughly 95 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Fulcrum Therapeutics.

Find out more about how you can short Fulcrum Therapeutics stock.

Fulcrum Therapeutics share dividends

We're not expecting Fulcrum Therapeutics to pay a dividend over the next 12 months.

Fulcrum Therapeutics share price volatility

Over the last 12 months, Fulcrum Therapeutics's shares have ranged in value from as little as $6.85 up to $33.098. A popular way to gauge a stock's volatility is its "beta".

FULC.US volatility(beta: 1.47)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulcrum Therapeutics's is 1.4661. This would suggest that Fulcrum Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Fulcrum Therapeutics overview

Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc.

Frequently asked questions

What percentage of Fulcrum Therapeutics is owned by insiders or institutions?
Currently 6.714% of Fulcrum Therapeutics shares are held by insiders and 74.333% by institutions.
How many people work for Fulcrum Therapeutics?
Latest data suggests 73 work at Fulcrum Therapeutics.
When does the fiscal year end for Fulcrum Therapeutics?
Fulcrum Therapeutics's fiscal year ends in December.
Where is Fulcrum Therapeutics based?
Fulcrum Therapeutics's address is: 26 Landsdowne Street, Cambridge, MA, United States, 02139
What is Fulcrum Therapeutics's ISIN number?
Fulcrum Therapeutics's international securities identification number is: US3596161097
What is Fulcrum Therapeutics's CUSIP number?
Fulcrum Therapeutics's Committee on Uniform Securities Identification Procedures number is: 359616109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site